Ram N. Ganapathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ram N. Ganapathi has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Mahrukh K. Ganapathi
Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
5 shared publications- David L. Tait
Charlotte, North Carolina
3 shared publications - Eric J. Norris
Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA
3 shared publications Jai N. Patel
Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
3 shared publications- Jalid Sehouli
Department of Gynecology with Center for Oncological Surgery, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany
3 shared publications - Mahrukh K. Ganapathi
Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
3 shared publications
Latest Publications
- Open Access
- 16 October 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (2) , 473-477
Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines
All trans retinoic acid (ATRA) has demonstrated curative activity in acute promyelocytic leukemia (APL), a distinct subtype of acute myeloid leukemia (AML), that is characterized by a chromosomal t...
- 16 October 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (2) , 473-477
Open AccessDexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines
All trans retinoic acid (ATRA) has demonstrated curative activity in acute promyelocytic leukemia (APL), a distinct subtype of acute myeloid leukemia (AML), that is characterized by a chromosomal t...
- Open Access
- 15 October 2018
- Published by Springer Nature in British Journal of Cancer
- Vol. 119 (9) , 1060-1066
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
Homologous recombination deficiency (HRD) is shown to predict response to DNA-damaging therapies in patients with high-grade serous ovarian cancer (HGSOC); however, changes in HRD during progression remains unknown. HRD scores were evaluated in paired primary and/or recurrent HGSOC samples (N = 107) from 54 patients with adjuvant platinum-based chemotherapy. BRCA1/2 mutation, BRCA1 methylation, loss of heterozygosity (LOH), and HRD scores were characterised using tumour DNA-based next-generation sequencing assays. Among 50 evaluable pairs (N = 100 samples), high intra-patient correlation in HRD score was observed (r2 = 0.93). BRCA1/2 mutations, BRCA1/2 LOH, and HRD were maintained between primary and recurrent samples, except for one pair in which a BRCA1 reversion mutation was identified in the recurrent sample. Despite the reversion, both samples were classified as having high HRD scores ( ≥ 42). All samples with BRCA1/2 mutations exhibited high HRD scores; however, high HRD scores were more prevalent than BRCA1/2 mutations (55% vs. 30%, respectively). Markers of HRD were maintained between the primary and recurrent samples, regardless of other genomic changes that occurred during recurrence. HRD score/markers in primary tumours may be valuable and adequate for selection of platinum-based therapy and/or poly-ADP-ribose-polymerase (PARP) inhibitors in recurrent HGSOC.
- 15 October 2018
- Published by Springer Nature in British Journal of Cancer
- Vol. 119 (9) , 1060-1066
Open AccessCharacterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
Homologous recombination deficiency (HRD) is shown to predict response to DNA-damaging therapies in patients with high-grade serous ovarian cancer (HGSOC); however, changes in HRD during progression remains unknown. HRD scores were evaluated in paired primary and/or recurrent HGSOC samples (N = 107) from 54 patients with adjuvant platinum-based chemotherapy. BRCA1/2 mutation, BRCA1 methylation, loss of heterozygosity (LOH), and HRD scores were characterised using tumour DNA-based next-generation sequencing assays. Among 50 evaluable pairs (N = 100 samples), high intra-patient correlation in HRD score was observed (r2 = 0.93). BRCA1/2 mutations, BRCA1/2 LOH, and HRD were maintained between primary and recurrent samples, except for one pair in which a BRCA1 reversion mutation was identified in the recurrent sample. Despite the reversion, both samples were classified as having high HRD scores ( ≥ 42). All samples with BRCA1/2 mutations exhibited high HRD scores; however, high HRD scores were more prevalent than BRCA1/2 mutations (55% vs. 30%, respectively). Markers of HRD were maintained between the primary and recurrent samples, regardless of other genomic changes that occurred during recurrence. HRD score/markers in primary tumours may be valuable and adequate for selection of platinum-based therapy and/or poly-ADP-ribose-polymerase (PARP) inhibitors in recurrent HGSOC.
- Open Access
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer
- Open Access
- 2 May 2017
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 45 (10) , 5995-6010
Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
Topoisomerase (topo) IIα and IIβ maintain genome stability and are targets for anti-tumor drugs. In this study, we demonstrate that the decatenation checkpoint is regulated, not only by topo IIα, as previously reported, but also by topo IIβ. The decatenation checkpoint is most efficient when both isoforms are present. Regulation of this checkpoint and sensitivity to topo II-targeted drugs is influenced by the C-terminal domain (CTD) of the topo II isoforms and by a conserved non-catalytic tyrosine, Y640 in topo IIα and Y656 in topo IIβ. Deletion of most of the CTD of topo IIα, while preserving the nuclear localization signal (NLS), enhances the decatenation checkpoint and sensitivity to topo II-targeted drugs. In contrast, deletion of most of the CTD of topo IIβ, while preserving the NLS, and mutation of Y640 in topo IIα and Y656 in topo IIβ inhibits these activities. Structural studies suggest that the differential impact of the CTD on topo IIα and topo IIβ function may be due to differences in CTD charge distribution and differential alignment of the CTD with reference to transport DNA. Together these results suggest that topo IIα and topo IIβ cooperate to maintain genome stability, which may be distinctly modulated by their CTDs.
- 2 May 2017
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 45 (10) , 5995-6010
Open AccessRoles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
Topoisomerase (topo) IIα and IIβ maintain genome stability and are targets for anti-tumor drugs. In this study, we demonstrate that the decatenation checkpoint is regulated, not only by topo IIα, as previously reported, but also by topo IIβ. The decatenation checkpoint is most efficient when both isoforms are present. Regulation of this checkpoint and sensitivity to topo II-targeted drugs is influenced by the C-terminal domain (CTD) of the topo II isoforms and by a conserved non-catalytic tyrosine, Y640 in topo IIα and Y656 in topo IIβ. Deletion of most of the CTD of topo IIα, while preserving the nuclear localization signal (NLS), enhances the decatenation checkpoint and sensitivity to topo II-targeted drugs. In contrast, deletion of most of the CTD of topo IIβ, while preserving the NLS, and mutation of Y640 in topo IIα and Y656 in topo IIβ inhibits these activities. Structural studies suggest that the differential impact of the CTD on topo IIα and topo IIβ function may be due to differences in CTD charge distribution and differential alignment of the CTD with reference to transport DNA. Together these results suggest that topo IIα and topo IIβ cooperate to maintain genome stability, which may be distinctly modulated by their CTDs.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e17046
Evaluation of homeobox (HOX) gene expression as a prognostic biomarker of time to recurrence (TTR) in high grade serous ovarian cancer (HGSOC) patients treated with adjuvant carboplatin plus paclitaxel (A-C/P).
E17046 Background: Aberrant HOX gene expression has been observed in various malignancies, including HGSOC. However, their role as a prognostic biomarker for TTR in HGSOC patients treated with A-C/P is unknown. Methods: RNA sequencing was conducted to determine HOX gene expression in a discovery cohort of primary tumors from 19 HGSOC patients treated with A-C/P. HOX genes associated with TTR in the discovery cohort and/or overall or disease-free survival in The Cancer Genome Atlas HGSOC data sets were selected for further testing by RT-PCR using the Fluidigm platform in an independent training cohort of primary tumors from 73 HGSOC patients treated with A-C/P. Univariate Cox proportional hazards models were used to identify HOX genes individually associated with TTR. Significant HOX genes (P<0.10) in the univariate analysis were included in a multivariable model applying backward elimination followed by forward selection. Risk groups were created by defining quartile cutoffs of the linear predictor from the final Cox model and analyzed using Kaplan-Meier techniques and Cox proportional hazards models. Results: Of the 37 HOX genes analyzed in the discovery cohort, 23 were selected for further analysis. Of these, HOXA2, A4, A7, A10, B2, B3, and D3 were individually associated with TTR in the training cohort. Multivariable analyses yielded HOXA4 and B3 in the final model (P=0.001 and P=0.016, respectively) with increasing expression levels associated with increased risk of recurrence. The prognostic index for HOXA4/B3 was significantly associated with TTR (Table 1, P=0.008). Conclusions: HOXA4/B3 gene expression was significantly associated with TTR in HGSOC and may serve as a potential prognostic biomarker. Ongoing studies include validation in larger patient cohorts treated with A-C/P and correlation of HOXA4/B3 expression with chemotherapy resistance and tumor recurrence.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e17046
Evaluation of homeobox (HOX) gene expression as a prognostic biomarker of time to recurrence (TTR) in high grade serous ovarian cancer (HGSOC) patients treated with adjuvant carboplatin plus paclitaxel (A-C/P).
E17046 Background: Aberrant HOX gene expression has been observed in various malignancies, including HGSOC. However, their role as a prognostic biomarker for TTR in HGSOC patients treated with A-C/P is unknown. Methods: RNA sequencing was conducted to determine HOX gene expression in a discovery cohort of primary tumors from 19 HGSOC patients treated with A-C/P. HOX genes associated with TTR in the discovery cohort and/or overall or disease-free survival in The Cancer Genome Atlas HGSOC data sets were selected for further testing by RT-PCR using the Fluidigm platform in an independent training cohort of primary tumors from 73 HGSOC patients treated with A-C/P. Univariate Cox proportional hazards models were used to identify HOX genes individually associated with TTR. Significant HOX genes (P<0.10) in the univariate analysis were included in a multivariable model applying backward elimination followed by forward selection. Risk groups were created by defining quartile cutoffs of the linear predictor from the final Cox model and analyzed using Kaplan-Meier techniques and Cox proportional hazards models. Results: Of the 37 HOX genes analyzed in the discovery cohort, 23 were selected for further analysis. Of these, HOXA2, A4, A7, A10, B2, B3, and D3 were individually associated with TTR in the training cohort. Multivariable analyses yielded HOXA4 and B3 in the final model (P=0.001 and P=0.016, respectively) with increasing expression levels associated with increased risk of recurrence. The prognostic index for HOXA4/B3 was significantly associated with TTR (Table 1, P=0.008). Conclusions: HOXA4/B3 gene expression was significantly associated with TTR in HGSOC and may serve as a potential prognostic biomarker. Ongoing studies include validation in larger patient cohorts treated with A-C/P and correlation of HOXA4/B3 expression with chemotherapy resistance and tumor recurrence.
- 5 March 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 141 (3) , 608-615
Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer
- 5 March 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 141 (3) , 608-615
Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer
- Open Access
- 27 August 2015
- Published by Wiley in International Journal of Cancer
- Vol. 138 (3) , 679-688
Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high‐grade serous ovarian cancer
Tumor recurrence, following initial response to adjuvant chemotherapy, is a major problem in women with high‐grade serous ovarian cancer (HGSOC). Microarray analysis of primary tumors has identified genes that may be useful in risk stratification/overall survival, but are of limited value in predicting the >70% rate for tumor recurrence. In this study, we performed RNA‐Seq analysis of primary and recurrent HGSOC to first identify unique differentially expressed genes. From this dataset, we selected 21 archetypical coding genes and one noncoding RNA, based on statistically significant differences in their expression profile between tumors, for validation by qPCR in a larger cohort of 110 ovarian tumors (71 primary and 39 recurrent) and for testing association of specific genes with time‐to‐recurrence (TTR). Kaplan–Meier tests revealed that high expression of collagen type II, alpha 1 (COL2A1) was associated with delayed TTR (HR = 0.47, 95% CI: 0.27–0.82, p = 0.008), whereas low expression of the pseudogene, solute carrier family 6 member 10 (SLC6A10P), was associated with longer TTR (HR = 0.53, 95% CI: 0.30–0.93, p = 0.027). Notably, TTR was significantly delayed for tumors that simultaneously highly expressed COL2A1 and lowly expressed SLC6A10P (HR = 0.21, 95% CI: 0.082–0.54, p = 0.0011), an estimated median of 95 months as compared to an estimated median of 16 months for subjects expressing other levels of COL2A1 and SLC6A10P. Thus, evaluating expression levels of COL2A1 and SLC6A10P at primary surgery could be beneficial for clinically managing recurrence of HGSOC.
- 27 August 2015
- Published by Wiley in International Journal of Cancer
- Vol. 138 (3) , 679-688
Open AccessExpression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high‐grade serous ovarian cancer
Tumor recurrence, following initial response to adjuvant chemotherapy, is a major problem in women with high‐grade serous ovarian cancer (HGSOC). Microarray analysis of primary tumors has identified genes that may be useful in risk stratification/overall survival, but are of limited value in predicting the >70% rate for tumor recurrence. In this study, we performed RNA‐Seq analysis of primary and recurrent HGSOC to first identify unique differentially expressed genes. From this dataset, we selected 21 archetypical coding genes and one noncoding RNA, based on statistically significant differences in their expression profile between tumors, for validation by qPCR in a larger cohort of 110 ovarian tumors (71 primary and 39 recurrent) and for testing association of specific genes with time‐to‐recurrence (TTR). Kaplan–Meier tests revealed that high expression of collagen type II, alpha 1 (COL2A1) was associated with delayed TTR (HR = 0.47, 95% CI: 0.27–0.82, p = 0.008), whereas low expression of the pseudogene, solute carrier family 6 member 10 (SLC6A10P), was associated with longer TTR (HR = 0.53, 95% CI: 0.30–0.93, p = 0.027). Notably, TTR was significantly delayed for tumors that simultaneously highly expressed COL2A1 and lowly expressed SLC6A10P (HR = 0.21, 95% CI: 0.082–0.54, p = 0.0011), an estimated median of 95 months as compared to an estimated median of 16 months for subjects expressing other levels of COL2A1 and SLC6A10P. Thus, evaluating expression levels of COL2A1 and SLC6A10P at primary surgery could be beneficial for clinically managing recurrence of HGSOC.
- 1 November 2014
- Published by Springer Nature
- p. 167-176
Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?
- 1 November 2014
- Published by Springer Nature
- p. 167-176
Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?
- 1 January 2014
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 32 (1) , 1-4
Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs
- 1 January 2014
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 32 (1) , 1-4
Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs